Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) EBIT (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed EBIT for 6 consecutive years, with -$23.9 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT rose 35.01% to -$23.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$129.4 million, a 3.99% increase, with the full-year FY2025 number at -$135.8 million, down 0.74% from a year prior.
  • EBIT was -$23.9 million for Q4 2025 at TScan Therapeutics, up from -$36.2 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$7.9 million in Q1 2021 to a low of -$36.7 million in Q4 2024.
  • A 5-year average of -$22.4 million and a median of -$22.0 million in 2023 define the central range for EBIT.
  • Peak YoY movement for EBIT: tumbled 120.92% in 2021, then skyrocketed 35.01% in 2025.
  • TScan Therapeutics' EBIT stood at -$14.2 million in 2021, then crashed by 31.31% to -$18.6 million in 2022, then dropped by 14.52% to -$21.4 million in 2023, then plummeted by 71.9% to -$36.7 million in 2024, then surged by 35.01% to -$23.9 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's EBIT are -$23.9 million (Q4 2025), -$36.2 million (Q1 2025), and -$36.7 million (Q4 2024).